Press Releases
Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit
Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the third-quarter in 2019, posting revenue of KRW 184.8 billion, operating profit of KRW 23.6 billion, and net profit of KRW 44.2 billion.
Sales increased by KRW 106.7 billion (136.6%)
compared to the previous quarter as a result of the end of Slow-Down* for regular maintenance at plant 1 and plant 2, and
sales recognition of products manufactured for PPQ (Process Performance Qualification)
run at P3.
Operating profit increased by KRW 39 billion
due to increased utilization rate at plant 1 and plant 2, and decreased
SG&A.
Net profit increased by KRW 57.5 billion in a
turnaround from the previous quarter, due to increased operating profit and equity
method gain from affiliated companies.
Compared to the same quarter last year, sales
increased by KRW 83.7 billion (82.8%), operating profit by KRW 13.1 billion
(124.8%), and net profit by KRW 71.1 billion.
※ Samsung
Biologics Financial Result 3Q 2019
(Billion KRW)
|
'19. 3Q
|
'19. 3Q
|
QoQ
|
'18. 3Q
|
YoY
|
Sales
|
184.8
|
78.1
|
+106.7 (136.6%)
|
101.1
|
+83.7 (82.8%)
|
Operating
Profit
|
23.6
|
-15.4
|
+39 (turnaround)
|
10.5
|
+13.1 (124.8%)
|
Net Profit
|
44.1
|
-13.4
|
+57.5 (turnaround)
|
-27
|
+71.1 (turnaround)
|
* Slow-Down:
Regular maintenance essential for biopharmaceutical manufacturing ? the plant operation rate temporarily decreases during this period.
Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once.
Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the third-quarter in 2019, posting revenue of KRW 184.8 billion, operating profit of KRW 23.6 billion, and net profit of KRW 44.2 billion.
Sales increased by KRW 106.7 billion (136.6%) compared to the previous quarter as a result of the end of Slow-Down* for regular maintenance at plant 1 and plant 2, and sales recognition of products manufactured for PPQ (Process Performance Qualification) run at P3.
Operating profit increased by KRW 39 billion due to increased utilization rate at plant 1 and plant 2, and decreased SG&A.
Net profit increased by KRW 57.5 billion in a turnaround from the previous quarter, due to increased operating profit and equity method gain from affiliated companies.
Compared to the same quarter last year, sales increased by KRW 83.7 billion (82.8%), operating profit by KRW 13.1 billion (124.8%), and net profit by KRW 71.1 billion.
※ Samsung Biologics Financial Result 3Q 2019 (Billion KRW)
| '19. 3Q | '19. 3Q | QoQ | '18. 3Q | YoY |
Sales | 184.8 | 78.1 | +106.7 (136.6%) | 101.1 | +83.7 (82.8%) |
Operating Profit | 23.6 | -15.4 | +39 (turnaround) | 10.5 | +13.1 (124.8%) |
Net Profit | 44.1 | -13.4 | +57.5 (turnaround) | -27 | +71.1 (turnaround) |
* Slow-Down:
Regular maintenance essential for biopharmaceutical manufacturing – the plant operation rate temporarily decreases during this period.
Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once.